Early epidemiological indicators, outcomes, and interventions of COVID-19 pandemic: A systematic review.


Journal

Journal of global health
ISSN: 2047-2986
Titre abrégé: J Glob Health
Pays: Scotland
ID NLM: 101578780

Informations de publication

Date de publication:
Dec 2020
Historique:
entrez: 28 10 2020
pubmed: 29 10 2020
medline: 5 11 2020
Statut: ppublish

Résumé

Coronavirus disease-2019 (COVID-19), a pandemic that brought the whole world to a standstill, has led to financial and health care burden. We aimed to evaluate epidemiological characteristics, needs of resources, outcomes, and global burden of the disease. Systematic review was performed searching PubMed from December 1, 2019, to March 25, 2020, for full-text observational studies that described epidemiological characteristics, following MOOSE protocol. Global data were collected from the JHU-Corona Virus Resource Center, WHO-COVID-2019 situation reports, KFF.org, and Worldometers.info until March 31, 2020. The prevalence percentages were calculated. The global data were plotted in excel to calculate case fatality rate (CFR), predicted CFR, COVID-19 specific mortality rate, and doubling time for cases and deaths. CFR was predicted using Pearson correlation, regression models, and coefficient of determination. From 21 studies of 2747 patients, 8.4% of patients died, 20.4% recovered, 15.4% were admitted to ICU and 14.9% required ventilation. COVID-19 was more prevalent in patients with hypertension (19.3%), smoking (11.3%), diabetes mellitus (10%), and cardiovascular diseases (7.4%). Common complications were pneumonia (82%), cardiac complications (26.4%), acute respiratory distress syndrome (15.7%), secondary infection (11.2%), and septic shock (4.3%). Though CFR and COVID-19 specific death rates are dynamic, they were consistently high for Italy, Spain, and Iran. Polynomial growth models were best fit for all countries for predicting CFR. Though many interventions have been implemented, stern measures like nationwide lockdown and school closure occurred after very high infection rates (>10cases per 100 000population) prevailed. Given the trend of government measures and decline of new cases in China and South Korea, most countries will reach the peak between April 1-20, if interventions are followed. A collective approach undertaken by a responsible government, wise strategy implementation and a receptive population may help contain the spread of COVID-19 outbreak. Close monitoring of predictive models of such indicators in the highly affected countries would help to evaluate the potential fatality if the second wave of pandemic occurs. The future studies should be focused on identifying accurate indicators to mitigate the effect of underestimation or overestimation of COVID-19 burden.

Sections du résumé

BACKGROUND BACKGROUND
Coronavirus disease-2019 (COVID-19), a pandemic that brought the whole world to a standstill, has led to financial and health care burden. We aimed to evaluate epidemiological characteristics, needs of resources, outcomes, and global burden of the disease.
METHODS METHODS
Systematic review was performed searching PubMed from December 1, 2019, to March 25, 2020, for full-text observational studies that described epidemiological characteristics, following MOOSE protocol. Global data were collected from the JHU-Corona Virus Resource Center, WHO-COVID-2019 situation reports, KFF.org, and Worldometers.info until March 31, 2020. The prevalence percentages were calculated. The global data were plotted in excel to calculate case fatality rate (CFR), predicted CFR, COVID-19 specific mortality rate, and doubling time for cases and deaths. CFR was predicted using Pearson correlation, regression models, and coefficient of determination.
RESULTS RESULTS
From 21 studies of 2747 patients, 8.4% of patients died, 20.4% recovered, 15.4% were admitted to ICU and 14.9% required ventilation. COVID-19 was more prevalent in patients with hypertension (19.3%), smoking (11.3%), diabetes mellitus (10%), and cardiovascular diseases (7.4%). Common complications were pneumonia (82%), cardiac complications (26.4%), acute respiratory distress syndrome (15.7%), secondary infection (11.2%), and septic shock (4.3%). Though CFR and COVID-19 specific death rates are dynamic, they were consistently high for Italy, Spain, and Iran. Polynomial growth models were best fit for all countries for predicting CFR. Though many interventions have been implemented, stern measures like nationwide lockdown and school closure occurred after very high infection rates (>10cases per 100 000population) prevailed. Given the trend of government measures and decline of new cases in China and South Korea, most countries will reach the peak between April 1-20, if interventions are followed.
CONCLUSIONS CONCLUSIONS
A collective approach undertaken by a responsible government, wise strategy implementation and a receptive population may help contain the spread of COVID-19 outbreak. Close monitoring of predictive models of such indicators in the highly affected countries would help to evaluate the potential fatality if the second wave of pandemic occurs. The future studies should be focused on identifying accurate indicators to mitigate the effect of underestimation or overestimation of COVID-19 burden.

Identifiants

pubmed: 33110589
doi: 10.7189/jogh.10.020506
pii: jogh-10-020506
pmc: PMC7567430
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

020506

Subventions

Organisme : NIGMS NIH HHS
ID : T32 GM062754
Pays : United States

Informations de copyright

Copyright © 2020 by the Journal of Global Health. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest: The authors completed the ICMJE Unified Competing Interest form (available upon request from the corresponding author), and declare no conflicts of interest.

Références

Int J Infect Dis. 2020 Apr;93:201-204
pubmed: 32097725
BMJ. 2020 Feb 19;368:m606
pubmed: 32075786
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Ann Intern Med. 2020 May 5;172(9):577-582
pubmed: 32150748
J Clin Med. 2020 Feb 17;9(2):
pubmed: 32079150
Clin Infect Dis. 2020 Mar 16;:
pubmed: 32173725
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):307-311
pubmed: 32191691
Epidemiol Health. 2020;42:e2020007
pubmed: 32035431
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Lancet Infect Dis. 2020 Jul;20(7):776-777
pubmed: 32224313
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Emerg Infect Dis. 2020 Jul;26(7):
pubmed: 32364890
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Euro Surveill. 2020 Mar;25(9):
pubmed: 32156327
Clin Infect Dis. 2020 Jul 28;71(15):769-777
pubmed: 32176772
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Nat Med. 2020 Aug;26(8):1193-1195
pubmed: 32504052
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
JAMA. 2020 Mar 17;323(11):1092-1093
pubmed: 32031568
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Commun Dis Intell (2018). 2020 Mar 11;44:
pubmed: 32156224
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Clin Infect Dis. 2020 Jul 28;71(15):756-761
pubmed: 32161968
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
MMWR Morb Mortal Wkly Rep. 2020 Feb 14;69(6):166-170
pubmed: 32053579
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632

Auteurs

Urvish Patel (U)

Department of Public Health, Icahn School of Medicine at Mount Sinai, New York, USA.

Preeti Malik (P)

Department of Public Health, Icahn School of Medicine at Mount Sinai, New York, USA.

Deep Mehta (D)

Clinical Research Program, Icahn School of Medicine at Mount Sinai, New York, USA.

Dhaivat Shah (D)

Clinical Research Program, Icahn School of Medicine at Mount Sinai, New York, USA.

Raveena Kelkar (R)

Clinical Research Program, Icahn School of Medicine at Mount Sinai, New York, USA.

Candida Pinto (C)

Department of Public Health, Icahn School of Medicine at Mount Sinai, New York, USA.

Maria Suprun (M)

Department of Pediatrics, Allergy, and Immunology, Icahn School of Medicine at Mount Sinai, New York, USA.

Mandip Dhamoon (M)

Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, USA.

Nils Hennig (N)

Department of Environmental Medicine and Public Health, Pediatric Infectious Diseases, Health System Design and Global Health, Icahn School of Medicine at Mount Sinai, New York, USA.

Henry Sacks (H)

Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH